Innate Pharma Sa's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Innate Pharma Sa's ROA in the fourth quarter of 2025?
Innate Pharma Sa recorded a cumulative net loss of $-55 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -78.41%.

However, within the Healthcare sector 780 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4864.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	-43.53 %	-43.53 %	-43.53 %	-43.53 %	-39.71 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-55	-55	-55	-55	-55
Return On Assets (TTM)	-78.41 %	-66.13 %	-56.94 %	-49.98 %	-44.54 %
IPHA's Total Ranking	# 4864	#	#	#	# 4729
Total Assets (TTM) in million	70	70	70	70	124
Seq. Total Assets Change	0 %	0 %	0 %	-43.53 %	0 %
Seq. Net Income Change	-	-	-	-	-

IPHA's 5 Years Annual ROA >> Back to IPHA Management Effectiveness >> Compare IPHA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 121
Sector	# 781
Overall	# 4823

Return On Assets Statistics
High	Average	Low
-4.11 %	-32.6 %	-78.41 %
(Dec 31 2023)		(Dec 31 2025)

Financial Statements
Innate Pharma Sa's Assets	$ 70 million	IPHA's Balance sheet
Innate Pharma Sa's Income	$ -55 million	Quarterly IPHA's Income Statement
IPHA's Income by Division		See IPHA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-43.53 %	-39.71 %	-11.39 %	-22.29 %	-12.99 %
Total Assets in million	70	124	206	233	300
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-55	-55	-8	-65	-59
Annual Return On Assets	-78.41 %	-44.54 %	-4.11 %	-27.95 %	-19.74 %

IPHA's 5 Years Annual ROA >> Back to IPHA Management Effectiveness >> Compare IPHA ROA to its Competitors

More Return On Assets Ratios
IPHA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IPHA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IPHA's Competitors
Subscribers only: Roa for Innate Pharma Sa's Suppliers
Subscribers only: Return On Assets for IPHA's Customers

You may also want to know
IPHA's Roi	IPHA's Inventory Turnover Ratio	IPHA's Growth Rates	IPHA's Dividend Comparisons
	IPHA's Profitability Ratios	IPHA's Asset Turnover Ratio	IPHA's Dividend Growth
IPHA's Roe	IPHA's Valuation Ratios	IPHA's Financial Strength Ratios	IPHA's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.